Hematology and Blood Disorders

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +1 (202) 780-3397

Editorial - Hematology and Blood Disorders (2025) Volume 8, Issue 2

From Injury to Clot: The Science of Coagulation and What Can Go Wrong

Ulrich Jaeger *

Department of Medicine, Yale University, New Haven, United States

*Corresponding Author:
Ulrich Jaeger
Department of Medicine,
Yale University, New Haven, United States
E-mail: ulrichjg@csl.gov.edu

Received: 01-Aug-2025, Manuscript No. AAHBD-24-171321; Editor assigned: 03-Aug-2025, PreQC No. AAHBD-24-171321(PQ);Reviewed:16-Aug-2025, QC No. AAHBD-24-171321; Revised:18-Aug-2025, Manuscript No. AAHBD-24-171321(R); Published: 24-Aug-2025, DOI:10.35841/AAHBD-8.2.224

Citation: Jaeger U. From injury to clot: The science of coagulation and what can go wrong. Hematol Blood Disord. 2025;8(2):224

Visit for more related articles at Hematology and Blood Disorders

Introduction

Blood coagulation is a marvel of biological engineering—a rapid, localized response to vascular injury that prevents excessive bleeding and preserves life. This intricate process, known as hemostasis, involves a cascade of cellular and molecular events that culminate in the formation of a stable blood clot. While essential for survival, the coagulation system is delicately balanced. Disruption can lead to either uncontrolled bleeding or pathological clot formation, both of which carry significant health risks [1].

The coagulation process is traditionally divided into three phases: initiation, amplification, and propagation. Initiation begins when blood vessels are injured, exposing subendothelial tissue factor (TF) to circulating blood. TF binds to factor VIIa, activating factor X to Xa, which converts prothrombin to thrombin. Amplification involves thrombin activating platelets and additional coagulation factors (V, VIII, XI), creating a positive feedback loop. Propagation sees the formation of the tenase and prothrombinase complexes on the surface of activated platelets, leading to a burst of thrombin generation and the conversion of fibrinogen to fibrin [2].

Fibrin strands weave through aggregated platelets to form a stable clot, sealing the injury site and allowing tissue repair to begin. Several components work in harmony to ensure effective clot formation: These cell fragments adhere to exposed collagen and release granules that recruit more platelets, forming a primary plug. These proteins circulate in an inactive form and are sequentially activated in the cascade. Key factors include VII, VIII, IX, X, and V. Fibrinogen is converted by thrombin into fibrin, which stabilizes the platelet plug into a durable clot. The goal of coagulation is to maintain hemostasis—preventing blood loss while keeping blood fluid within vessels. However, when this balance is disrupted, two major pathological outcomes can occur: Conditions like hemophilia (deficiency of factor VIII or IX) impair clot formation, leading to prolonged bleeding even from minor injuries [3].

D-dimer levels indicate fibrin degradation and are used to detect thrombotic events. Genetic Testing helps identify inherited conditions like hemophilia or thrombophilia. Management depends on the nature of the disorder: Drugs like warfarin, heparin, and direct oral anticoagulants (DOACs) prevent clot formation in thrombotic disorders. Excessive clotting can result in deep vein thrombosis (DVT), pulmonary embolism (PE), stroke, or myocardial infarction. These clots may form without injury and obstruct blood flow. A genetic disorder where clotting factor VIII (Hemophilia A) or IX (Hemophilia B) is deficient. Patients experience spontaneous bleeding into joints and muscles. Treatment involves factor replacement therapy. The most common inherited bleeding disorder, caused by a deficiency or dysfunction of von Willebrand factor, which helps platelets adhere to damaged vessels [4].

A paradoxical condition where widespread clotting depletes clotting factors, leading to simultaneous bleeding and thrombosis. It’s often triggered by sepsis, trauma, or malignancy. A group of disorders that increase the risk of abnormal clot formation. Examples include Factor V Leiden mutation and prothrombin gene mutation. An autoimmune condition where antibodies target phospholipid-binding proteins, increasing clot risk. It’s associated with recurrent miscarriages and strokes. Diagnosing coagulation disorders involves a combination of clinical evaluation and laboratory tests: Prothrombin Time (PT) and Activated Partial Thromboplastin Time (aPTT) assess the extrinsic and intrinsic pathways, respectively. Platelet Count and Bleeding Time evaluate primary hemostasis [5].

Conclusion

Aspirin and clopidogrel inhibit platelet aggregation and are used in cardiovascular disease. Hemophilia patients receive recombinant clotting factors. Used in mild hemophilia and von Willebrand disease to stimulate factor release. Agents like alteplase dissolve existing clots in emergencies like stroke or PE. Recent research highlights the interplay between coagulation and the immune system. Inflammatory cytokines can upregulate tissue factor expression, promoting clot formation. Conversely, clotting can amplify inflammation, creating a vicious cycle seen in conditions like sepsis and COVID-19-associated coagulopathy. Especially in patients on anticoagulants, to avoid interactions and bleeding complications. Advances in genomics, biotechnology, and personalized medicine are transforming coagulation management: Promising for hemophilia, aiming to correct the underlying genetic defect. For early detection of thrombotic risk. Such as factor XIa inhibitors, which may reduce clot risk with minimal bleeding.

References

  1. Patel SR, Hartwig JH, Italiano JE.The biogenesis of platelets from megakaryocyte proplatelets.J Clin Investig. 2005;115(12):3348-54.

    2. Indexed at, Google ScholarCross Ref

  2. Van der Meijden PE, Heemskerk JW.Platelet biology and functions: New concepts and clinical perspectivesNat Rev Cardiol. 2019;16(3):166-79.

    3. Indexed at, Google Scholar,Cross Ref

  3. Ruggeri ZM.Platelets in atherothrombosis.Nat Med. 2002;8(11):1227-34.

    4. Indexed at, Google Scholar,Cross Ref

  4. Koupenova M, Kehrel BE, Corkrey HA et al.Thrombosis and platelets: An updateEur Heart J. 2017;38(11):785-91.

    5. Indexed at, Google Scholar,Cross Ref

  5. Lambert MP, Sullivan SK, Fuentes R et al.Challenges and promises for the development of donor-independent platelet transfusions Blood, Am J Hematol. 2013;121(17):3319-24.

    6. Indexed at, Google Scholar,Cross Ref

Get the App